SESSION TYPE: DVT/PE/Pulmonary Hypertension Posters II
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: The computational simulation is a very powerful tool for investigation of physical and biological properties of blood flow in different organs. One important factor in the general behaviour of blood flow is the geometrical properties of the vessel. In-vivo studies show that the behaviour of blood flow through the vessels is dependent on its diameter. Our objective is to investigate the impact of the vessel diameter in different orders of a typical pulmonary vascular system on the behaviour of blood flow by developing a computational fluid model.
METHODS: Our laboratory devised a unique computational fluid dynamics (CFD) model. CFD is the numerical analysis of systems involving different parameters such as geometry, fluid flow, and associated phenomena by computer-based simulation through a complex array of softwares.
RESULTS: We obtained the three-dimensional distributions of velocity, shear stress, and pressure drop in different orders of pulmonary vessels. We also studied the non-Newtonian behaviour of blood flow for different flow conditions. The effect of flow rate (based on cardiac output) as one of the significant parameters on pressure drop was also studied. We compared our work to previous studies where different methods performed to investigate the blood flow in different arterial networks demonstrated that the flow can vary from a simple one-dimensional flow to a complex three-dimensional and turbulent flow.
CONCLUSIONS: We conclude that the one-dimensional model of blood flow is valid for arbitrary small vessels and the three-dimensional simulation is more accurate in the larger vessels.
CLINICAL IMPLICATIONS: Blood flow physics and dynamics play important roles in identification of pathophysiology of diseases of the vascular system. The science can be implicated in studying the impact of shear stress on pulmonary endothelial system and could significantly contribute to better understanding of pulmonary hypertension. This in turn could facilitate drug design for this disease.
DISCLOSURE: The following authors have nothing to disclose: Houman Tammadon, Mehrdad Behnia, Leonard Kritharides, Masud Behnia, Mehrdad Behnia
No Product/Research Disclosure InformationDoctors Hospital, Augusta, GA